Regulatory Oversight on Pediatric Fixed-Dose Combinations: Strengthening Drug Safety Standards

The Union Government, acting under Section 26A of the Drugs and Cosmetics Act, 1940, has introduced stringent regulatory measures concerning the manufacture and sale of Fixed Dose Combinations (FDCs) containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride. This policy intervention follows critical recommendations from the Drugs Technical Advisory Board (DTAB), which identified potential health risks associated with the administration of these specific combinations to infants and young children. Under the new mandate, pharmaceutical manufacturers are legally obligated to include a prominent warning on product packaging, explicitly stating that these medications are contraindicated for children below four years of age. This regulatory action is a significant step in enhancing pharmacovigilance and ensuring that over-the-counter (OTC) medications meet rigorous safety standards, particularly for vulnerable demographics. The decision reflects a proactive approach by the health ministry to mitigate the risks of adverse drug reactions and improper dosage in pediatric care, where physiological responses to chemical compounds differ significantly from those of adults.